{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:15:38Z","timestamp":1780629338188,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11033-022-07888-y","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T10:04:07Z","timestamp":1664359447000},"page":"12247-12252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation"],"prefix":"10.1007","volume":"49","author":[{"given":"Susanne","family":"Bracher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Jeromin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niroshan","family":"Nadarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"7888_CR1","doi-asserted-by":"publisher","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines. Blood 111(12):5446-56. https:\/\/doi.org\/10.1182\/blood-2007-06-093906","DOI":"10.1182\/blood-2007-06-093906"},{"issue":"8","key":"7888_CR2","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","volume":"121","author":"D Rossi","year":"2013","unstructured":"Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C et al (2013) Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121(8):1403\u20131412. https:\/\/doi.org\/10.1182\/blood-2012-09-458265","journal-title":"Blood"},{"issue":"26","key":"7888_CR3","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, Leupolt E, Kr\u00f6ber A, Bullinger L, D\u00f6hner K, Bentz M, Lichter M (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343(26):1910\u20131916. https:\/\/doi.org\/10.1056\/NEJM200012283432602","journal-title":"N Engl J Med"},{"issue":"3","key":"7888_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","volume":"31","author":"A Stengel","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C (2017) The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 31(3):705\u2013711. https:\/\/doi.org\/10.1038\/leu.2016.263","journal-title":"Leukemia"},{"issue":"6","key":"7888_CR5","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al (1999) Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. Blood 94(6):1840\u20131847. https:\/\/doi.org\/10.1182\/blood.V94.6.1840","journal-title":"Blood"},{"issue":"6","key":"7888_CR6","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999) Unmutated Ig V(H) Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia. Blood 94(6):1848\u20131854. https:\/\/doi.org\/10.1182\/blood.V94.6.1848","journal-title":"Blood"},{"issue":"11","key":"7888_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F et al (2019) Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 133(11):1205\u20131216. https:\/\/doi.org\/10.1182\/blood-2018-09-873083","journal-title":"Blood"},{"issue":"21","key":"7888_CR8","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, D\u00f6hner K et al (2014) Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123(21):3247\u20133254. https:\/\/doi.org\/10.1182\/blood-2014-01-546150","journal-title":"Blood"},{"issue":"8","key":"7888_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/bjc.2016.78","volume":"114","author":"D Rossi","year":"2016","unstructured":"Rossi D, Gaidano G (2016) The clinical implications of gene mutations in chronic lymphocytic leukaemia. Br J Cancer 114(8):849\u2013854. https:\/\/doi.org\/10.1038\/bjc.2016.78","journal-title":"Br J Cancer"},{"issue":"2","key":"7888_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.2003.08.005","volume":"21","author":"T Haferlach","year":"2003","unstructured":"Haferlach T, Schoch C, L\u00f6ffler H, Gassmann W, Kern W, Schnittger S et al (2003) Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 21(2):256\u2013265. https:\/\/doi.org\/10.1200\/JCO.2003.08.005","journal-title":"J Clin Oncol"},{"issue":"3","key":"7888_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/cyto.b.21002","volume":"82","author":"W Kern","year":"2012","unstructured":"Kern W, Bacher U, Haferlach C, Alpermann T, Dicker F, Schnittger S, Haferlach T (2012) Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom 82(3):145\u2013150. https:\/\/doi.org\/10.1002\/cyto.b.21002","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"7888_CR12","first-page":"1640","volume":"8","author":"E Matutes","year":"1994","unstructured":"Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, Catovsky D (1994) The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8(10):1640\u20131645","journal-title":"Leukemia"},{"key":"7888_CR13","volume-title":"WHO Classification of Tumours of Haematopoietic and Lympoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J et al (2008) WHO Classification of Tumours of Haematopoietic and Lympoid Tissues. IARC, Lyon"},{"issue":"9","key":"7888_CR14","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1182\/blood-2006-02-005322","volume":"108","author":"F Dicker","year":"2006","unstructured":"Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C (2006) Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 108(9):3152\u20133160. https:\/\/doi.org\/10.1182\/blood-2006-02-005322","journal-title":"Blood"},{"key":"7888_CR15","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan J, Simons A, Schmid M (eds. ISCN 2016) An International System for Human Cytogenomic Nomenclature. Basel, New York:Karger","DOI":"10.1159\/isbn.978-3-318-06861-0"},{"issue":"1","key":"7888_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/leu.2013.263","volume":"28","author":"K Bayer","year":"2014","unstructured":"Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V et al \u00a0(2014) SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 28(1):108\u2013117. https:\/\/doi.org\/10.1038\/leu.2013.263.","journal-title":"Leukemia"},{"issue":"1","key":"7888_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/leu.2008.274","volume":"23","author":"F Dicker","year":"2009","unstructured":"Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, Kern W, Haferlach T, Haferlach C (2009) The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23(1):117\u2013124. https:\/\/doi.org\/10.1038\/leu.2008.274","journal-title":"Leukemia"},{"key":"7888_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jmoldx.2013.03.003","volume":"15","author":"V Grossmann","year":"2013","unstructured":"Grossmann V, Roller A, Klein HU, Weissmann S, Kern W, Haferlach C et al (2013) Robustness of amplicon deep sequencing underlines its utility in clinical applications. J Mol Diagn 15:473\u2013484. https:\/\/doi.org\/10.1016\/j.jmoldx.2013.03.003","journal-title":"J Mol Diagn"},{"issue":"10","key":"7888_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/gcc.22087","volume":"52","author":"A Navarro","year":"2013","unstructured":"L\u00f3pez C, Delgado J, Costa D, Villamor N, Navarro A, Cazorla M et al \u00a0(2013) Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. Genes Chromosomes Cancer 52(10):920\u2013927. https:\/\/doi.org\/10.1002\/gcc.22087.","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"7888_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","volume":"126","author":"R Gui\u00e8ze","year":"2015","unstructured":"Gui\u00e8ze R, Wu CJ (2015) Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood 126(4):445\u2013453. https:\/\/doi.org\/10.1182\/blood-2015-02-585042","journal-title":"Blood"},{"issue":"9","key":"7888_CR21","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3324\/haematol.10720","volume":"92","author":"E Leupolt","year":"2007","unstructured":"Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D et al \u00a0(2007) Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 92(9):1242\u20131245. https:\/\/doi.org\/10.3324\/haematol.10720.","journal-title":"Haematologica"},{"issue":"2","key":"7888_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/ejh.12215","volume":"92","author":"E Wawrzyniak","year":"2014","unstructured":"Wawrzyniak E, Kotkowska A, Blonski JZ, Siemieniuk-Rys M, Ziolkowska E, Giannopoulos K, Robak T, Korycka-Wolowiec A (2014) Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance. Eur J Haematol 92(2):91\u2013101. https:\/\/doi.org\/10.1111\/ejh.12215","journal-title":"Eur J Haematol"},{"issue":"8","key":"7888_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3324\/haematol.2010.039768","volume":"96","author":"R Gunnarsson","year":"2011","unstructured":"Gunnarsson R, Mansouri L, Isaksson A, G\u00f6ransson H, Cahill N, Jansson M et al (2011) Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 96(8):1161\u20131169. https:\/\/doi.org\/10.3324\/haematol.2010.039768","journal-title":"Haematologica"},{"key":"7888_CR24","doi-asserted-by":"publisher","unstructured":"Raponi S, Ilari C, Della Starza I, Cappelli LV, Cafforio L, Piciocchi A et al  (2020). Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. Br J Haematol 189(5):853\u2013859. https:\/\/doi.org\/10.1111\/bjh.16434.","DOI":"10.1111\/bjh.16434"},{"key":"7888_CR25","doi-asserted-by":"publisher","unstructured":"Moia R, Patriarca A, Schipani M, Ferri V, Favini C, Sagiraju S et al (2020) Precision Medicine Management of Chronic Lymphocytic Leukemia. Cancers (Basel) 10;12(3):642. doi: https:\/\/doi.org\/10.3390\/cancers12030642","DOI":"10.3390\/cancers12030642"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07888-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07888-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07888-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:49:24Z","timestamp":1669837764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07888-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7888"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07888-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CH, WK, and TH declare part ownership of Munich Leukemia Laboratory (MLL). SB, IF, SJ, NN, and AS are employed by the MLL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients had given a written informed consent, to the use of laboratory data according to the Declaration of Helsinki. The study was conducted in accordance with the Declaration of Helsinki and the Ethics Committee of the Bavarian State Medical Association.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}